CD BioSciences Announces Cytoskeleton-Targeted Tumor Marker Development Service for Cancer Diagnosis
CD BioSciences has announced its cytoskeleton-based tumor marker development service for cancer diagnosis. CD BioSciences, a prominent biotech company, has recently unveiled its latest and innovative service on cytoskeleton-based tumor marker development. This groundbreaking service can be utilized for preclinical tests to determine the tumor type and predict disease Continue Reading
CD BioSciences Pioneers the Frontier of Marine Drug Development
CD BioSciences has announced its marine drug development services for anticancer therapies, pioneering a new frontier in novel drug R&D. Recently, CD BioSciences has announced the release of marine drug development services aiming to move forward the frontier of this area. Utilizing cutting-edge marine biological analysis techniques and unique Continue Reading
New Technology to Promote Drug Development-AI Technology
For a long time, the research and development of each new drug has faced the challenges of high cost and long cycle. In response to these challenges, major pharmaceutical companies have shifted from targeting common diseases to developing drugs for specific diseases. At the same time, these companies are constantly Continue Reading
What is Nanogel and Its Classifications?
Nanogels (NGs), namely nanoscale hydrogel particles, are three-dimensional network systems formed by physical or chemical cross-linking of polymers. Nanogels have received widespread attention in recent years due to their unique properties and potential applications in various fields such as drug delivery, tissue engineering, and diagnostics. Classification of Nanogels According to the Continue Reading
What are Radionuclide Drug Conjugates (RDCs)?
Coupling drugs combine the precise targeting and potent killing properties, has become a widely recognized form of medication in recent years. Radioactive drug conjugates (RDCs), as a particular form of coupling drugs, are formed by combining radioactive isotopes with disease-targeting molecules. According to the application of RDCs, they can be Continue Reading
BOC Sciences to Present Its Novel Solutions at the 2024 TIDES USA Conference
BOC Sciences, a globally renowned supplier with over a decade of experience in the biochemical supply chain, is thrilled to announce its participation in this year’s TIDES USA or the Oligonucleotide and Peptide Therapeutics conference. The BOC Sciences team will showcase its cutting-edge products and services at booth #937. TIDES USA 2024 is Continue Reading
Overview of ADC Combination Therapies
Antibody-drug conjugates (ADCs) have emerged as a promising class of treatments in the evolving field of cancer treatment. ADCs combine the potency of cytotoxic drugs with the selectivity of monoclonal antibodies, providing a novel approach to targeted therapy. ADCs show great promise in the fight against cancer and have the potential Continue Reading